Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC; SUMMIT/CREST Investigators.

Blood. 2005 Dec 1;106(12):3777-84. Epub 2005 Aug 11.

PMID:
16099887
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.

Cancer. 2005 Nov 15;104(10):2141-8.

PMID:
16206291
[PubMed - indexed for MEDLINE]
Free Article
3.

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators.

Cancer. 2005 Mar 15;103(6):1195-200.

PMID:
15690325
[PubMed - indexed for MEDLINE]
Free Article
4.

A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.

Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, Onishi Y, Fujiwara Yamada M, Ishizawa K, Kameoka J, Harigae H.

Int J Hematol. 2009 Apr;89(3):342-7. doi: 10.1007/s12185-009-0279-4. Epub 2009 Mar 19.

PMID:
19296199
[PubMed - indexed for MEDLINE]
5.

Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.

Richardson P, Jagannath S, Colson K.

Clin Adv Hematol Oncol. 2006 May;4(5):1; discussion 8; suppl 13.

PMID:
16830422
[PubMed - indexed for MEDLINE]
6.

Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.

Freimann H, Calderoni A, Cornu P, Olie R.

Swiss Med Wkly. 2007 Jun 2;137(21-22):317-22.

PMID:
17629810
[PubMed - indexed for MEDLINE]
Free Article
7.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.

J Clin Oncol. 2006 Jul 1;24(19):3113-20. Epub 2006 Jun 5.

PMID:
16754936
[PubMed - indexed for MEDLINE]
Free Article
8.

[Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].

Bao L, Lu XJ, Zhang XH, Huang XJ.

Zhonghua Yi Xue Za Zhi. 2008 Jul 8;88(26):1829-31. Chinese.

PMID:
19040018
[PubMed - indexed for MEDLINE]
9.

Optimizing bortezomib treatment in patients with relapsed multiple myeloma.

Richardson P.

Clin Adv Hematol Oncol. 2006 May;4(5):4-5; discussion 8; suppl 13. No abstract available.

PMID:
16832859
[PubMed - indexed for MEDLINE]
10.

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.

Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Bladé J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL.

Br J Haematol. 2008 Oct;143(2):222-9. doi: 10.1111/j.1365-2141.2008.07321.x. Epub 2008 Aug 18.

PMID:
18713253
[PubMed - indexed for MEDLINE]
11.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.

Br J Haematol. 2007 Jun;137(5):429-35. Epub 2007 Apr 19.

PMID:
17451408
[PubMed - indexed for MEDLINE]
12.

Expanding role of bortezomib in multiple myeloma: nursing implications.

Colson K, Doss DS, Swift R, Tariman J.

Cancer Nurs. 2008 May-Jun;31(3):239-49. doi: 10.1097/01.NCC.0000305733.80592.8e.

PMID:
18453881
[PubMed - indexed for MEDLINE]
13.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J.

Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.

PMID:
19170677
[PubMed - indexed for MEDLINE]
14.

Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.

Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS.

Clin Adv Hematol Oncol. 2008 Oct;6(10):755-60.

PMID:
18997666
[PubMed - indexed for MEDLINE]
15.

A practical update on the use of bortezomib in the management of multiple myeloma.

San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H.

Oncologist. 2006 Jan;11(1):51-61. Review.

PMID:
16401713
[PubMed - indexed for MEDLINE]
Free Article
16.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

PMID:
17654660
[PubMed - indexed for MEDLINE]
Free Article
17.

Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.

Quach H, Horvath N, Cannell P, Mikhael JR, Butcher BE, Prince HM.

Intern Med J. 2009 May;39(5):290-5. doi: 10.1111/j.1445-5994.2008.01738.x. Epub 2008 Jun 28.

PMID:
19371392
[PubMed - indexed for MEDLINE]
18.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A.

J Clin Oncol. 2006 Oct 20;24(30):4867-74. Epub 2006 Sep 25.

PMID:
17001068
[PubMed - indexed for MEDLINE]
Free Article
19.

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R.

Ann Hematol. 2008 Aug;87(8):623-31. doi: 10.1007/s00277-008-0501-0. Epub 2008 May 8.

PMID:
18463870
[PubMed - indexed for MEDLINE]
20.

[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].

Huang WR, Li R, Jing Y, Zhang YZ, Wu XX, Gao CJ, Bo J, Yu L, Wang QS, Da WM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec;14(6):1146-50. Chinese.

PMID:
17204182
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk